title: Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women.
abstract: Recent studies suggest that HIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies contribute to protective immunity against HIV. An important characteristic of future HIV vaccines will, therefore, be the ability to stimulate production of these antibodies in both men and women. Early studies suggest that men may have a better ADCC antibody response against HIV than women. Our objective was to determine whether men and women differ with respect to their ADCC response to HIV-1 gp120. HIV-positive, asymptomatic untreated men and women were matched for race, age, CD4(+) T cell number, HIV-1 viral load, and treatment and HIV-1 gp120 ADCC antibody titers were compared. A standard (51)Cr-release assay was used to determine HIV-1 gp120 ADCC antibody titers in HIV-1-seropositive individuals from the Multicenter AIDS Cohort Study (MACS; n=32) and the Women's Interagency HIV Study (WIHS; n=32). Both sexes had high ADCC titers against HIV-1 gp120: 34.4% (n=11) and 40.6% (n=13) of men and women, respectively, had titers of 10,000; 62.5% (n=20) and 56.3% (n=18) had titers of 100,000. Groups did not differ in percent specific release (% SR), lytic units (LU), correlations of titer to viral load, or titer to CD4(+) T cells in men or women. Both groups also had similar cross-clade ADCC antibody responses (p>0.5 for % SR and LU). Comparable groups of asymptomatic HIV-1-infected men and women had comparable HIV-1 gp120 ADCC antibodies. Both sexes had significant cross-clade reactivity. Differences between men and women may become evident as disease progresses; this should be evaluated at later stages of HIV-1 infection.
authors: 1 Department of Immunology and Microbiology, Rush University Medical Center , Chicago, Illinois.
authors: Mariana M
authors: MM
authors: Mata
authors: Joyce R
authors: JR
authors: Iwema
authors: Shanna
authors: S
authors: Dell
authors: Leslie
authors: L
authors: Neems
authors: Beth D
authors: BD
authors: Jamieson
authors: John
authors: J
authors: Phair
authors: Mardge H
authors: MH
authors: Cohen
authors: Kathryn
authors: K
authors: Anastos
authors: Linda L
authors: LL
authors: Baum
mesh_terms: D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D058345:Asymptomatic Infections / Q000453:epidemiology*; D018791:CD4 Lymphocyte Count; D003601:Cytotoxicity Tests, Immunologic; D018450:Disease Progression; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019562:Viral Load
chemical_list: D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C514793:gp120 protein, Human immunodeficiency virus 1
references: AIDS. 1997 Dec;11(15):17-36
references: 9412719
references: Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10532-7
references: 10984542
references: Viral Immunol. 2011 Oct;24(5):359-68
references: 21958370
references: AIDS Res Hum Retroviruses. 2003 Oct;19(10):929-32
references: 14601595
references: AIDS. 1997 Mar;11(3):389-91
references: 9147436
references: Epidemiology. 1998 Mar;9(2):117-25
references: 9504278
references: J Infect Dis. 1997 Apr;175(4):795-800
references: 9086132
references: N Engl J Med. 2009 Dec 3;361(23):2209-20
references: 19843557
references: J Immunol Methods. 1984 Mar 30;68(1-2):235-49
references: 6200539
references: J Infect Dis. 1999 Oct;180(4):1338-41
references: 10479168
references: Viral Immunol. 2011 Apr;24(2):171-5
references: 21449728
references: Lancet. 1998 Nov 7;352(9139):1510-4
references: 9820299
references: J Clin Immunol. 2001 May;21(3):227-33
references: 11403230
references: J Infect Dis. 2004 Dec 1;190(11):1970-8
references: 15529262
references: J Infect Dis. 2002 Feb 15;185(4):439-47
references: 11865395
references: J Virol. 1996 Oct;70(10):7013-29
references: 8794346
references: Proc Natl Acad Sci U S A. 2011 May 3;108(18):7505-10
references: 21502492
references: Cancer Immunol Immunother. 2012 Nov;61(11):1905-16
references: 22465967
references: Lancet. 1999 Feb 13;353(9152):589; author reply 590-1
references: 10029004
references: N Engl J Med. 2012 Apr 5;366(14):1275-86
references: 22475592
references: J Infect Dis. 1999 Sep;180(3):666-72
references: 10438353
references: AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):553-61
references: 11350669
references: J Virol. 2011 Jul;85(14):7029-36
references: 21543485
references: PLoS Pathog. 2012;8(6):e1002739
references: 22719248
references: J Immunol. 1996 Sep 1;157(5):2168-73
references: 8757343
references: Am J Epidemiol. 1987 Aug;126(2):310-8
references: 3300281
references: J Virol. 2012 Nov;86(22):12039-52
references: 22933282
references: PLoS Pathog. 2012;8(8):e1002890
references: 22927823
references: J Virol. 2012 Nov;86(21):11521-32
references: 22896626
references: J Virol. 2012 Aug;86(16):8672-80
references: 22674985
references: J Virol. 2012 Jun;86(11):6189-96
references: 22457527
references: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7
references: 16940858
references: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):127-31
references: 21792067
references: Curr HIV/AIDS Rep. 2010 Feb;7(1):11-8
references: 20425053
references: J Virol. 2011 Jul;85(14):6906-12
references: 21593181